Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in ...

Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

Medical device company ICU Medical (NASDAQ:ICUI) will be reporting results tomorrow after market close. Here’s what you need ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

Artivion (AORT) delivered earnings and revenue surprises of -100% and 3.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...

Artivion beat analysts’ revenue expectations by 0.5% last quarter, reporting revenues of $95.78 million, up 9% year on year. It was a very strong quarter for the company, with an impressive beat of ...

In a report released today, Frank Takkinen from Lake Street reiterated a Buy rating on Artivion (AORT – Research Report), with a price target ...

Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% ...

ATLANTA - Artivion, Inc. (NYSE: AORT) saw its shares plunge 10% after-hours Monday after the cardiac and vascular surgery company reported fourth quarter revenue that fell short of analyst ...